GPT yields 0.75% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, GPT + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GPT + ABBV for your $10,000?
GPT is designed to be highly dynamic, relying on both AI and human expertise to capitalize on evolving market opportunities. The strategy integrates human insight with AI-powered stock selection to construct a portfolio of global large-cap stocks. Portfolio construction begins with an analyst setting the portfolios parameters, including structure, concentration limits, and thematic inspiration from renowned trading strategies. AI then analyzes datasets to identify four to six major trading trends to choose positions that align with these trends based on key financial metrics such as revenue growth and earnings. Three independent AI models select 20 to 30 stocks to form an equal-weighted portfolio, with no single position exceeding 10%. The selection process combines both quantitative and qualitative analysis. Portfolio rebalancing is done quarterly to ensure compliance. The fund is expected to have a high portfolio turnover rate. Prior to Sept. 29, 2025, the fund name was Intelligent Livermore ETF and traded under the ticker LIVR.
Full GPT Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.